About Tyra Biosciences:Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables the rapid and precise refinement of structural drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.

About Bristol Myers Squibb:We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Turning Point Therapeutics:Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients.

About La Jolla Pharmaceuticals:La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

(Daiichi Sankyo aquired previous employer)Responsible for all aspects of Information Technology at Daiichi Sankyo(San Diego) as well as providing EITSM leadership for all Quality Assurance Applications for Daiichi Sankyo Incorporated, R&D(US).About Daiichi Sankyo:Our worldwide research and development network connects Japan, the United States, Europe, India and East Asian countries. Our R&D function, including Daiichi Sankyo Novare and Asubio Pharma, is primarily based at four sites in Japan. They collaborate with Daiichi Sankyo Group companies in the US, Europe and Asia, on everything from drug discovery to development and pharmaceutical technology research. In clinical trials, this wealth of expertise from around the world is shared to carry out global decision-making.In the United States, Daiichi Sankyo Pharma Development (DSPD) oversees global clinical trials from Edison, New Jersey, while in the UK, Daiichi Sankyo Development in London oversees clinical trials in Europe. What’s more, other bases in Asia, such as Daiichi Sankyo Korea, Daiichi Sankyo Taiwan, Daiichi Sankyo (China), and Daiichi Sankyo India Development, contribute to the continued introduction of new products onto the market.

About Ambit Biosciences(Aquired by Daiichi Sankyo in 2015):Ambit is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications. Our lead compound, quizartinib, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently under clinical investigation in patients with relapsed or refractory AML.

About Getronics:The Getronics family is an ICT Services group consisting of the Getronics and Connectis brands and is owned by the AURELIUS Group, a holding company headquartered in Munich, Germany. With an extensive history that extends over 125 years, the Getronics family has approximately 6,000 employees in 18 countries across Europe, Asia Pacific & Latin America, and has a complete portfolio of integrated ICT services for the large enterprise and public sector markets. This includes Workspace, Applications, Communication, Data Centre, Cloud, Consulting, Product and Managed Services.

About GNF:The Genomics Institute of the Novartis Research Foundation (GNF) serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization, the Novartis Institutes for BioMedical Research (NIBR). GNF’s nearly 600 scientists and engineers are committed to pushing the boundaries of science in pursuit of new medicines. Multi-disciplinary teams are focused on making advances in the areas of oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. GNF has world-class expertise in high-throughput drug screening, highly-parallel cell-based assays, and other advanced automation technologies, which enable its researchers to tackle the complexity of biological systems in seeking to address unmet medical need.